Elecsys EBV VCA IgG
Roche Diagnostics · Decision date Oct 2, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision on 2026-10-02 for Elecsys EBV VCA IgG, a 510(k) submitted by Roche Diagnostics of Indianapolis, Indiana, under K260232. The device falls under classification name Epstein-Barr Virus, Other, regulation 866.3235, product code LSE, with microbiology as the regulation medical specialty and review panel. The application was received on 01/26/2026 and reviewed as a traditional 510(k); the record states it was not reviewed by a third party, is not a combination product, and has no authorized predetermined change control plan.
SESE means FDA cleared the submission as substantially equivalent to a legally marketed predicate device; it is not premarket approval of the product. The same FDA listing of final decisions dated 2026-10-02 also shows K260221 Elecsys EBV EBNA IgG and K260233 Elecsys EBV IgM, both from Roche Diagnostics and both substantially equivalent, indicating a related group of submissions decided the same day. The record does not identify the predicate device, the intended use statement, analytical or clinical performance data, or the components and methods of the assay, so those details remain unknown from this source.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Microbiology
- Decision date
- Oct 2, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K260232
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Roche Diagnostics
- Product code
- LSE
- Decision code
- SESE
- Decision date
- Oct 2, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Epstein-Barr Virus, Other.
- Applicant
- Roche Diagnostics
- Product code
- LSE
- FDA device class
- 1
FDA decision timeline
K260232 received
Application receipt date recorded by FDA.
K260232 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code LSE
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Elecsys EBV EBNA IgGK260221 | Roche Diagnostics | 510(k) clearance | Oct 2, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Roche Diagnostics
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Indianapolis, IN
Sources and methodology
- Original FDA record: K260232
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records